TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03530163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Breathing Training
Description: Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
Study: NCT01691313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanoxerine
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanoxerine
Description: single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study: NCT04845971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saisei Maf capsules
Description: Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
Study: NCT03325881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465
Description: SHP465 capsule 6.25 mg orally once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to SHP465 capsule orally once daily for 4 weeks
Study: NCT05740098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practices
Description: Five As plus referral to a quit line

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practices
Description: Five As plus referral to a quit line

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practices
Description: Five As plus referral to a quit line

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Nicotine patches and gum/lozenge provided together for dual therapy
Study: NCT02243579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04101396

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: diabetic diet
Description: Patients with gestational diabetes will be seen by the dietitian to be taught diet modification

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: diabetic diet
Description: Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
Study: NCT00570635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL820
Description: XL820 capsules administered orally as a single agent at a dose of 800 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL820
Description: XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
Study: NCT00489177

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A
Description: QuickOpt intra-cardiac electrogram optimization

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: B
Description: Single optimization in initial month post-implant
Study: NCT03887884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Description: Levodopa Inhalation Powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet
Description: Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
Study: NCT01090206

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D and calcium
Description: Doses will be based on Vitamin D levels
Study: NCT00408447

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Busulfan 4 mg/kg/d x 4d

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Busulfan 4 mg/kg/d x 4d

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/d x 6d

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/d x 6d

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab
Description: Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab
Description: Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
Study: NCT00834717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride 1 mg tablets
Description: 2 x 1 mg, single dose fasting
Study: NCT00408447

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic stem cell transplant
Description: Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic stem cell transplant
Description: Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
Study: NCT00127933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 825mg/m2 po bid on days 1-14 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75mg/m2 iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin (HER2-neu positive patients only)
Description: 4mg/kg iv (loading dose) followed by 2mg/kg iv weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 825mg/m2 po bid on days 1-14 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75mg/m2 iv on day 1 of each 3 week cycle
Study: NCT03093168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: dose: 25mg/m2/d
Study: NCT00834717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril® 1 mg tablets
Description: 2 x 1 mg, single dose fasting
Study: NCT04492540

Intervention type: OTHER
Group type: OTHER
Intervention: aerobic exercise and MIND diet program
Description: the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
Study: NCT03093168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose: 40mg/kg
Study: NCT04299620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Image Analysis
Description: Analysis of images

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo standard of care radical prostatectomy
Study: NCT04492540

Intervention type: OTHER
Group type: OTHER
Intervention: MIND diet program
Description: control group will receive diet program for 12 weeks
Study: NCT04299620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal Ultrasound
Description: Undergo transrectal ultrasound
Study: NCT04833608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vktory insoles
Description: Patients were randomized into either the Carbon fiber insole group or Morton's extension group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Morton's extension insoles
Description: Patients were randomized into either the Vktory carbon fiber insole group or Morton's extension insole group.
Study: NCT00498485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Oxybate
Description: Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
Study: NCT03111732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
Study: NCT05249400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-site assistance
Description: The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
Study: NCT02781701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Trainer
Description: The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks.
Study: NCT01903200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral
Study: NCT02181140

Intervention type: DEVICE
Group type: OTHER
Intervention: EUS guided FNA and fine needle punction
Description: punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
Study: NCT03723044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG and occulometry
Description: Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
Study: NCT02125461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
Study: NCT00161421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: 24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
Study: NCT02811354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: oral administration as a single daily dose of 80 mg
Study: NCT03135301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole plus metformin
Description: letrozole 5 milligram tablets plus metformin 850 milligram tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: letrozole 5 milligram tablets
Study: NCT03311061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DREAMS Curriculum
Description: Teen Pregnancy Prevention Curriculum as described in arm/group description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DREAMS Curriculum
Description: Teen Pregnancy Prevention Curriculum as described in arm/group description.
Study: NCT02517554

Intervention type: BEHAVIORAL
Intervention: Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site
Description: Baseline and follow up survey

Intervention type: BEHAVIORAL
Intervention: Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site
Description: Baseline and follow up surveys

Intervention type: BEHAVIORAL
Intervention: Patient receives written information on how to find genetic services in their area
Description: Baseline and follow up surveys
Study: NCT03110991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
Description: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
Description: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
Study: NCT04632550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential pulmonary vein isolation(CPVI) group
Description: 1. PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Evaluation of procedure time, radiofrequency ablation time~4. Evaluation of the complication after the procedure.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior box isolation(POBI) group
Description: 1. PVI will be performed using a radiofrequency catheter~2. Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POBI+Anterior linear ablation(AL) group
Description: 1. PVI, POBI will be performed using a radiofrequency catheter~2. Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study: NCT01926119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study: NCT01501786

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control
Description: propofol 8mg/kg/h saline 0.24 ml/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ket10
Description: propofol 6.4 mg/kg/h ketamine 10 microg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ket20
Description: propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
Study: NCT01116739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: Fluoride varnish will be administered by the COHS quarterly for 2 years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral health education
Description: Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
Study: NCT03043469

Intervention type: OTHER
Intervention: The Self-evaluation of breathing questionnaire
Description: Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed

Intervention type: OTHER
Intervention: The Self-evaluation of breathing questionnaire
Description: Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed

Intervention type: OTHER
Intervention: six-minute exercise test
Description: Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
Study: NCT01116739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental services delivered by the Indian Health Service.
Study: NCT02645500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic health training and physical exercise messages
Description: The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Holistic Health Training with healthy diet messages
Description: The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
Study: NCT03487081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social regulation
Description: Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self regulation
Description: Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
Study: NCT01849003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally
Study: NCT00392873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EAMD+Calories
Description: During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
Study: NCT02163369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint and Lavender Essential Oils
Study: NCT03566966

Intervention type: BIOLOGICAL
Intervention: Non-organ-specific Ab positive
Description: Antiviral administration and evaluation of SVR24 and side effects

Intervention type: BIOLOGICAL
Intervention: Non-organ-specific Ab negative
Description: direct-acting antiviral agents
Study: NCT01626040

Intervention type: DRUG
Intervention: polyethylene glycol powder
Description: A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
Study: NCT03043469

Intervention type: OTHER
Intervention: six-minute exercise test
Description: Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).

Intervention type: OTHER
Intervention: six-minute exercise test
Description: Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
Study: NCT01505062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR421869
Description: Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection